本文選題：血必凈注射液 + 急性非ST段抬高型心肌梗死�。� 參考：《中國(guó)藥房》2017年23期

【摘要】：目的:探討血必凈注射液對(duì)急性非ST段抬高型心肌梗死(NSTEMI)患者的炎癥因子、氧化應(yīng)激水平和血栓風(fēng)險(xiǎn)的影響以及用藥安全性。方法:選取2015年5月-2016年8月我院收治的NSTEMI患者130例作為研究對(duì)象,按照隨機(jī)數(shù)字表法分為對(duì)照組和觀察組,各65例。對(duì)照組患者給予降壓、降脂、抗凝和抗血小板等常規(guī)治療;觀察組患者在對(duì)照組基礎(chǔ)上給予血必凈注射液50 m L,ivgtt,q12 h。兩組患者均連續(xù)治療1周。觀察兩組患者治療前后血清炎癥因子[腫瘤壞死因子α(TNF-α)、白細(xì)胞介素6(IL-6)、IL-10和超敏C反應(yīng)蛋白(hs-CRP)]、超氧化物歧化酶(SOD)、丙二醛(MDA)、基質(zhì)金屬蛋白酶9(MMP-9)、血小板集聚率和纖維蛋白原水平,并記錄治療過(guò)程以及治療后1個(gè)月內(nèi)MACE和出血事件的發(fā)生情況。結(jié)果:治療前,兩組患者炎癥因子、SOD、MDA、MMP-9、血小板集聚率和纖維蛋白原水平比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者TNF-α、IL-6、hs-CRP、血小板聚集率和纖維蛋白原水平均明顯降低,IL-10水平明顯升高,且觀察組患者上述指標(biāo)改善程度均明顯優(yōu)于對(duì)照組。兩組患者SOD和MMP-9水平均明顯升高,MDA水平明顯降低;觀察組患者SOD水平明顯高于對(duì)照組,MDA水平明顯低于對(duì)照組,但MMP-9水平明顯低于對(duì)照組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者的MACE發(fā)生率(16.92%vs.20.00%)和出血事件發(fā)生率(4.62%vs.7.69%)比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:血必凈注射液治療NSTEMI療效顯著,可有效抑制患者的炎癥和氧化應(yīng)激水平,降低血栓形成風(fēng)險(xiǎn),且安全性較高。
[Abstract]:Objective: to investigate the effects of Xuebijing injection on inflammatory factors, oxidative stress and thrombus risk in patients with acute non-ST-segment elevation myocardial infarction (AMI). Methods: one hundred and thirty patients with NSTEMI from May 2015 to August 2016 were randomly divided into two groups: control group and observation group. The patients in the control group were treated with antihypertensive, lipid-lowering, anticoagulant and anti-platelet therapy, and the patients in the observation group were treated with Xuebijing injection 50 mL iv GTT q12 h on the basis of the control group. The patients in both groups were treated continuously for 1 week. Before and after treatment, serum inflammatory factors (TNF- 偽, IL-6, IL-10 and hs-CRP), superoxide dismutase (SOD), malondialdehyde (MDA), matrix metalloproteinase-9 (MMP-9), platelet aggregation and fibrinogen levels were observed in both groups. The course of treatment and the occurrence of MACE and bleeding events within 1 month after treatment were recorded. Results: before treatment, there was no significant difference in the levels of MDAMDA-9, platelet aggregation and fibrinogen between the two groups (P 0.05). After treatment, the levels of TNF- 偽 IL-6hs-CRP, platelet aggregation and fibrinogen were significantly decreased in both groups, and the improvement of the above indexes in the observation group was significantly better than that in the control group. The levels of SOD and MMP-9 in the two groups were significantly higher than those in the control group, and the levels of SOD in the observation group were significantly higher than those in the control group, but the MMP-9 level was significantly lower than that in the control group (P 0.05). There was no significant difference between the two groups in the incidence of MACE (16.92 vs 20.00) and the incidence of bleeding events (4.62% vs 7.69). Conclusion: Xuebijing injection is effective in the treatment of NSTEMI. It can effectively inhibit inflammation and oxidative stress and reduce the risk of thrombosis.
【作者單位】： 漯河市中心醫(yī)院藥劑科;漯河市中心醫(yī)院呼吸內(nèi)科;漯河市中心醫(yī)院心內(nèi)科;
【分類號(hào)】：R542.22

【相似文獻(xiàn)】

相關(guān)期刊論文 前6條

1 張奎;;聯(lián)合應(yīng)用血必凈注射液治療慢性肺源性心臟病急性期的臨床研究[J];醫(yī)藥論壇雜志;2011年17期

2 王瑞峰;;血必凈注射液治療老年性肺心病急性加重期患者臨床觀察[J];臨床合理用藥雜志;2012年17期

3 王建明;;血必凈注射液治療老年急性冠脈綜合征臨床觀察[J];中國(guó)實(shí)用醫(yī)藥;2010年31期

4 李繼紅;徐國(guó)良;林淑梅;秦玲;;血必凈注射液治療慢性肺心病心力衰竭有效性及安全性的系統(tǒng)評(píng)價(jià)[J];中國(guó)中醫(yī)急癥;2012年05期

5 曾慶壽;藍(lán)鵬;;血必凈注射液聯(lián)合西醫(yī)治療慢性肺源性心臟病急性期30例臨床分析[J];嶺南急診醫(yī)學(xué)雜志;2008年03期

6 王煜霞;王雷;姬明麗;;血必凈注射液對(duì)家兔左心缺血再灌注損傷肺臟的保護(hù)作用[J];河南師范大學(xué)學(xué)報(bào)(自然科學(xué)版);2013年06期

相關(guān)會(huì)議論文 前1條

1 李洪艷;雒云祥;;血必凈注射液對(duì)高血壓患者癥狀及血流變學(xué)的影響[A];第六屆全國(guó)危重病學(xué)術(shù)交流大會(huì)論文匯編[C];2005年

，

本文編號(hào)：1918531